Achieve Life Sciences (ACHV)

• Market cap: $106M
• 1 day: 0.65%
• 5 days: -8.31%
• 1 month: -25.72%
• 3 months: -38.81%
• 6 months: -36.42%
• Year to date: -16.26%
• 1 year: -28.47%
• 5 years: -75.78%
• 10 years: -99.32%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

Employees: 22

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,739% more call options, than puts

Call options by funds: $1.8M | Put options by funds: $98K

333% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 3

50% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 12

14% more funds holding

Funds holding: 56 [Q2] → 64 (+8) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

1% less capital invested

Capital invested by funds: $81.7M [Q2] → $81.3M (-$419K) [Q3]

6.79% less ownership

Funds ownership: 56.14% [Q2] → 49.34% (-6.79%) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12 288% upside
• Avg. target: $12 288% upside
• High target: $12 288% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Rodman & Renshaw Brandon Folkes 54% 1-year accuracy 7 / 13 met price target

288% upside $12

Buy Initiated

14 Nov 2024